The BLAZE‑4 Study is testing treatments to prevent mild to moderate COVID‑19 symptoms from becoming severe. COVID-19 is particularly concerning for people who may be at greater risk of developing severe symptoms. Eli Lilly and Company, a US-based pharmaceutical company, is conducting the BLAZE‑4 Study to meet this urgent need.
The BLAZE‑4 Study is for people 12 years and older who have been tested for COVID-19 in the last 3 days. Most research sites are offering in‑home appointments. Some participants will receive a placebo, but all participants who are at high risk for developing severe COVID‑19 symptoms are now guaranteed to receive investigational medicine.
Only people who have had a COVID‑19 test in the last 3 days may be eligible for the BLAZE‑4 Study. If you or your child have had a COVID‑19 test in the last 3 days, it's important to begin the prequalification process as soon as possible. To do so, click the I'm Interested button and complete the steps that follow.
The BLAZE‑4 Study is available to people ages 12 and older with COVID-19 symptoms, who took a test to confirm their diagnosis in the last 3 days. Most research sites are offering in‑home appointments.
The BLAZE‑4 Study is testing whether investigational medicines could prevent the progression of mild to moderate COVID‑19 to severe COVID‑19. The investigational medicines are a common type of drug that scientists make to mimic a part of the body's immune system, but they are not vaccines.
Each person and each research study are different. Every research study has risks and benefits to consider when deciding whether to participate. If you or your child qualify, you and those close to you are the only ones who can decide if participation is the right choice.
You may want to take part in this study for the following reasons:
Move COVID‑19 research forward and possibly help find a treatment that may help others
Take an active role in your or your child's health by staying informed and exploring new potential treatment options
Possibly try one or more investigational medicines for COVID‑19 that are available through this study